A new study could lead millions more Americans to take cholesterol-lowering drugs and generate billions in sales for AstraZeneca, which funded it. But first comes a furious debate.
The study, called Jupiter, gave either AstraZeneca's (nyse: AZN - news - people ) Crestor or placebo to 18,000 patients who received bad scores on a little-known blood test for C-reactive protein (CRP) that is thought to measure inflammation in the arteries. 
Patients who took Crestor were half as likely to have heart attacks, strokes or operations to open clogged arteries as those getting placebo, an effect that ranks among the best results seen with the two-decade old class of cholesterol drugs called statins, of which Crestor is the most potent.
Mas...La prensa económica ha dado una amplia cobertura a estos resultados y especula sobre sus implicaciones económicas para Astra Zeneca.
Mas...
Sin embargo en Astra mantienen la reserva...
Mas...
Ver: Nuevas ventajas de los fármacos anticolesterol
Entradas
No hay comentarios:
Publicar un comentario